Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study

Asthma is a chronic inflammatory airway disease, representing one of the most severe pathologies in developed countries. Based on a report of the World Health Organization (WHO), it affects about 300 million people worldwide. Few studies have analyzed the effects of daily life physical activity (PA)...

Full description

Bibliographic Details
Main Authors: Giovanna Elisiana Carpagnano, Francesco Sessa, Giulia Scioscia, Donato Lacedonia, Maria Pia Foschino, Maria Pia Venuti, Antonio Ivano Triggiani, Anna Valenzano, Onofrio Resta, Giuseppe Cibelli, Giovanni Messina
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-01-01
Series:Frontiers in Pharmacology
Subjects:
mepolizumab
omalizumab
physical activity
severe asthma
quality of life
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2019.01630/full

Internet

https://www.frontiersin.org/article/10.3389/fphar.2019.01630/full

Similar Items